Inhibikase Therapeutics, Inc. – NASDAQ:IKT
Inhibikase Therapeutics stock price today
Inhibikase Therapeutics stock price monthly change
Inhibikase Therapeutics stock price quarterly change
Inhibikase Therapeutics stock price yearly change
Inhibikase Therapeutics key metrics
Market Cap | 210.64M |
Enterprise value | 7.11M |
P/E | -0.85 |
EV/Sales | 54.77 |
EV/EBITDA | -0.26 |
Price/Sales | 107.36 |
Price/Book | 0.66 |
PEG ratio | -0.07 |
EPS | -3.38 |
Revenue | N/A |
EBITDA | -19.97M |
Income | -19.20M |
Revenue Q/Q | -100% |
Revenue Y/Y | -2.88% |
Profit margin | -21027.98% |
Oper. margin | -21085.25% |
Gross margin | 5.04% |
EBIT margin | -21085.25% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInhibikase Therapeutics stock price history
Inhibikase Therapeutics stock forecast
Inhibikase Therapeutics financial statements
$6.5
Potential upside: 275.72%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 116.41K | -5.77M | -4963.46% |
|---|---|---|---|
| Sep 2023 | 79.56K | -4.59M | -5775.11% |
| Dec 2023 | 1 | -4.17M | -417794000% |
| Mar 2024 | 0 | -4.64M |
| Jun 2023 | 22347387 | 2.88M | 12.9% |
|---|---|---|---|
| Sep 2023 | 17880702 | 2.86M | 16.01% |
| Dec 2023 | 14506647 | 3.52M | 24.32% |
| Mar 2024 | 11068098 | 4.29M | 38.77% |
| Jun 2023 | -4.56M | 2.54M | -35.98K |
|---|---|---|---|
| Sep 2023 | -4.10M | 17.06M | 70 |
| Dec 2023 | -3.44M | -2.11M | -138.10K |
| Mar 2024 | -3.86M | -3.31M | 366.99K |
Inhibikase Therapeutics alternative data
| Aug 2023 | 6 |
|---|---|
| Sep 2023 | 6 |
| Oct 2023 | 6 |
| Nov 2023 | 6 |
| Dec 2023 | 6 |
| Jan 2024 | 6 |
| Feb 2024 | 6 |
| Mar 2024 | 6 |
| Apr 2024 | 6 |
| May 2024 | 8 |
| Jun 2024 | 8 |
| Jul 2024 | 8 |
Inhibikase Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Nov 2021 | 400 | 0 |
| May 2022 | 18948 | 0 |
| Aug 2022 | 5000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | WERNER MILTON H. director, 10 perc.. | Common Stock | 5,000 | $0.8 | $4,000 | ||
Purchase | WERNER MILTON H. director, 10 perc.. | Common Stock | 5,000 | $0.98 | $4,880 | ||
Purchase | WERNER MILTON H. director, 10 perc.. | Common Stock | 10,000 | $0.6 | $6,000 | ||
Purchase | FRATTAROLI JOSEPH officer: Chief Financial Officer | Common Stock | 3,948 | $0.64 | $2,543 | ||
Option | WERNER MILTON H. director, 10 perc.. | Stock Option (right to buy) | 21,853 | $2.02 | $44,143 | ||
Option | WERNER MILTON H. director, 10 perc.. | Common Stock | 21,853 | $2.02 | $44,143 | ||
Purchase | WERNER MILTON H. director, 10 perc.. | Common Stock | 400 | $1.93 | $772 | ||
Option | WERNER MILTON H. director, 10 perc.. | Common Stock | 21,853 | $2.02 | $44,143 | ||
Option | WERNER MILTON H. director, 10 perc.. | Stock Option (right to buy) | 21,853 | $2.02 | $44,143 | ||
Option | WERNER MILTON H. director, 10 perc.. | Common Stock | 43,707 | N/A | N/A |
| Patent |
|---|
Application Filling date: 5 Jan 2021 Issue date: 6 May 2021 |
Grant Filling date: 26 Jun 2019 Issue date: 2 Feb 2021 |
Application Filling date: 25 Oct 2017 Issue date: 13 Feb 2020 |
Application Filling date: 26 Jun 2019 Issue date: 30 Jan 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 17 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q2 2023 15 Nov 2023 | Q2 2023 Earnings Call Transcript |
| Q3 2023 15 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Milton H. Werner (1963) Chief Executive Officer, Pres & Director | $307,340 |
Mr. Joseph Frattaroli CPA (1962) Chief Financial Officer | $300,000 |
-
What's the price of Inhibikase Therapeutics stock today?
One share of Inhibikase Therapeutics stock can currently be purchased for approximately $1.73.
-
When is Inhibikase Therapeutics's next earnings date?
Unfortunately, Inhibikase Therapeutics's (IKT) next earnings date is currently unknown.
-
Does Inhibikase Therapeutics pay dividends?
No, Inhibikase Therapeutics does not pay dividends.
-
How much money does Inhibikase Therapeutics make?
Inhibikase Therapeutics has a market capitalization of 210.64M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 111.03% to 260.5K US dollars.
-
What is Inhibikase Therapeutics's stock symbol?
Inhibikase Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "IKT".
-
What is Inhibikase Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Inhibikase Therapeutics?
Shares of Inhibikase Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Inhibikase Therapeutics's key executives?
Inhibikase Therapeutics's management team includes the following people:
- Dr. Milton H. Werner Chief Executive Officer, Pres & Director(age: 62, pay: $307,340)
- Mr. Joseph Frattaroli CPA Chief Financial Officer(age: 63, pay: $300,000)
-
How many employees does Inhibikase Therapeutics have?
As Jul 2024, Inhibikase Therapeutics employs 8 workers, which is 33% more then previous quarter.
-
When Inhibikase Therapeutics went public?
Inhibikase Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 23 Dec 2020.
-
What is Inhibikase Therapeutics's official website?
The official website for Inhibikase Therapeutics is inhibikase.com.
-
Where are Inhibikase Therapeutics's headquarters?
Inhibikase Therapeutics is headquartered at 3350 Riverwood Parkway SE, Atlanta, GA.
-
How can i contact Inhibikase Therapeutics?
Inhibikase Therapeutics's mailing address is 3350 Riverwood Parkway SE, Atlanta, GA and company can be reached via phone at +678 3923419.
-
What is Inhibikase Therapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Inhibikase Therapeutics in the last 12 months, the avarage price target is $6.5. The average price target represents a 275.72% change from the last price of $1.73.
Inhibikase Therapeutics company profile:
Inhibikase Therapeutics, Inc.
inhibikase.comNASDAQ
8
Biotechnology
Healthcare
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Atlanta, GA 30339
CIK: 0001750149
ISIN: US45719W2052
CUSIP: 45719W106
